Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies
Open Access
- 1 September 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 8 (5)
Abstract
Objective To compare the humoral response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with multiple sclerosis (MS) receiving different disease-modifying treatments (DMTs). Methods Patients with MS with coronavirus disease 2019 (COVID-19) and available anti–SARS-CoV-2 serology were included. The primary endpoint was the anti–SARS-CoV-2 immunoglobulin G (IgG) index. The multivariate analysis was adjusted for COVID-19 severity, SARS-CoV-2 PCR result, and the time between COVID-19 onset and the serology. Results We included 61 patients with available IgG index. The IgG index was lower in patients with fingolimod or anti-CD20 monoclonal antibodies compared with patients without treatment (p < 0.01), patients with interferon β-1a or glatiramer (p < 0.01), and patients with another DMT (p = 0.01). The IgG index was correlated with the time between COVID-19 onset and serology (r = −0.296 [−0.510; −0.0477], p = 0.02). Conclusions Humoral response after COVID-19 was lower in patients with MS with fingolimod or anti-CD20 mAb. These patients could therefore be at risk of recurrent infection and could benefit from anti–SARS-CoV-2 vaccination. The humoral response after vaccination and the delay before vaccination need to be evaluated. Classification of Evidence This study provides Class IV evidence that patients treated with fingolimod or anti-CD20 monoclonal antibodies for MS have a lower humoral response after COVID-19 compared with patients without DMTs or with another DMTs.Keywords
This publication has 12 references indexed in Scilit:
- The presence of SARS-CoV2 antibodies in MS patientsMultiple Sclerosis and Related Disorders, 2021
- Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patientsMultiple Sclerosis and Related Disorders, 2021
- Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple SclerosisAnnals of Neurology, 2021
- Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?Multiple Sclerosis and Related Disorders, 2020
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosisNeurology, 2020
- Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumabMultiple Sclerosis and Related Disorders, 2020
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisJAMA Neurology, 2020
- Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemiaMultiple Sclerosis and Related Disorders, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19New England Journal of Medicine, 2020
- Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosisNeurology, 2015